JP2022500079A5 - - Google Patents
Info
- Publication number
- JP2022500079A5 JP2022500079A5 JP2021538176A JP2021538176A JP2022500079A5 JP 2022500079 A5 JP2022500079 A5 JP 2022500079A5 JP 2021538176 A JP2021538176 A JP 2021538176A JP 2021538176 A JP2021538176 A JP 2021538176A JP 2022500079 A5 JP2022500079 A5 JP 2022500079A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- modified
- oligomer compound
- modified oligonucleotide
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862729067P | 2018-09-10 | 2018-09-10 | |
| US62/729,067 | 2018-09-10 | ||
| US201962891127P | 2019-08-23 | 2019-08-23 | |
| US62/891,127 | 2019-08-23 | ||
| PCT/US2019/050476 WO2020055917A1 (en) | 2018-09-10 | 2019-09-10 | Compounds and methods for modulating cln3 expression |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022500079A JP2022500079A (ja) | 2022-01-04 |
| JP2022500079A5 true JP2022500079A5 (cg-RX-API-DMAC7.html) | 2022-09-21 |
| JP7511563B2 JP7511563B2 (ja) | 2024-07-05 |
Family
ID=69777155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021538176A Active JP7511563B2 (ja) | 2018-09-10 | 2019-09-10 | Cln3の発現を調節するための化合物及び方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20220280545A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3849564A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7511563B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020055917A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY203356A (en) | 2018-01-12 | 2024-06-25 | Bristol Myers Squibb Co | Antisense oligonucleotides targeting alpha-synuclein and uses thereof |
| WO2019140236A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Antisense oligonucleotides targeting alpha-synuclein and uses thereof |
| WO2022150369A1 (en) * | 2021-01-06 | 2022-07-14 | Exicure Operating Company | Compounds for the treatment of batten disease |
| WO2025091028A1 (en) * | 2023-10-27 | 2025-05-01 | The Regents Of The University Of Michigan | Compounds and methods for modulating cln3 expression |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2305813A3 (en) * | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| US7314750B2 (en) * | 2002-11-20 | 2008-01-01 | Affymetrix, Inc. | Addressable oligonucleotide array of the rat genome |
| EP2285961A4 (en) * | 2008-05-15 | 2012-10-17 | Topigen Pharmaceuticals Inc | OLIGONUCLEOTIDES FOR THE TREATMENT OF INFLAMMATION AND NEOPLASTIC CELL REPRODUCTION |
| JP2014054185A (ja) * | 2011-01-12 | 2014-03-27 | Astellas Pharma Inc | 新規braf融合体の検出法 |
| MY192689A (en) * | 2013-10-11 | 2022-09-01 | Ionis Pharmaceuticals Inc | Compositions for modulating c9orf72 expression |
| DK3077510T3 (da) * | 2013-12-02 | 2020-06-08 | Ionis Pharmaceuticals Inc | Antisense-forbindelser og anvendelser deraf |
| EA201790551A1 (ru) * | 2014-09-07 | 2017-07-31 | Селекта Байосайенсиз, Инк. | Способы и композиции для ослабления иммунных ответов к пропускающему экзон вирусному трансферному вектору |
| WO2016061263A1 (en) * | 2014-10-14 | 2016-04-21 | Ionis Pharmaceuticals, Inc. | Antisense compounds and uses thereof |
| IL308717A (en) * | 2015-12-07 | 2024-01-01 | Genzyme Corp | Methods and compositions for treating a serpinc1-associated disorder |
| WO2022150369A1 (en) * | 2021-01-06 | 2022-07-14 | Exicure Operating Company | Compounds for the treatment of batten disease |
-
2019
- 2019-09-10 WO PCT/US2019/050476 patent/WO2020055917A1/en not_active Ceased
- 2019-09-10 US US17/274,981 patent/US20220280545A1/en active Pending
- 2019-09-10 JP JP2021538176A patent/JP7511563B2/ja active Active
- 2019-09-10 EP EP19859762.7A patent/EP3849564A4/en active Pending